Jaguar Health (JAGX)
Develops and supplies crofelemer treatments for intestinal failure and diarrhea in people and animals.
Something off on this page? Send us feedback.
Develops crofelemer for rare intestinal-failure diseases and supplies human and canine diarrhea products through a U.S. licensee. The business combines botanical sourcing, outsourced manufacturing, regulatory development, and licensing, with its pipeline concentrated on one molecule.
Develops crofelemer powder for oral solution as an adjunct to parenteral support in microvillus inclusion disease and short bowel syndrome with intestinal failure. Coordinates botanical sourcing, outsourced manufacturing, regulatory development, and licensing; development activity spans the United States, European Union, and Middle East. Direct product activity includes non-prescription Neonorm digestive-health products, while Gelclair's current commercial status is unresolved in reviewed sources.
Supplies Mytesi for noninfectious diarrhea in adults with HIV/AIDS and Canalevia-CA1 for chemotherapy-induced diarrhea in dogs to Future Pak, the exclusive U.S. commercial licensee. Its business depends on third-party manufacturing, Amazonian plant-latex collection, regulatory acceptance, licensee performance, and clinical progress from a crofelemer-centered pipeline.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 25, 2026 | BOCOM International Holdings Company | Target | Target: — | Target: $3.21 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $6.6M · Total debt $16.7M · Total assets $34.2M · Shareholders' equity $6.6M
- Revenue
- $1.2M
- Operating income
- −$7.6M
- Net income
- −$12.7M
No dividends on record.
| Institutions | 0.14% | 488 shares | |
|---|---|---|---|
| 10 holders · as of Mar 31, 2026 | |||
| Insiders | 0.06% | 198 shares | |
| 9 holders · as of Mar 12, 2026 | |||
| Other | 99.80% | 343.9K shares | |
| remainder | |||
344.6K company shares as of Sep 23, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (344.6K in the company's Sep 23, 2026 report, 434.1K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
UBS Group AGInstitution | 0.06% | 112,906 | as of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 0.06% | 110,129 | as of Mar 31, 2026 |
Lisa A. ConteInsiderdirector, officer: See Remarks | 0.02% | 56 | filed Jan 21, 2026 |
HRT Financial LPInstitution | 0.01% | 15,187 | as of Mar 31, 2026 |
Two Sigma Securities, LLCInstitution | 0.01% | 12,551 | as of Mar 31, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Takeda (ADR)
Approved SBS-IF treatment versus an investigational oral alternative.
- Ironwood Pharmaceuticals
Late-stage SBS-IF treatment versus an investigational oral alternative.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Jaguar Health | $9.28 | −73.08% | $15.0M | — | — | 0.5 | −58.9% |
| Takeda (ADR) | $18.82 | −0.71% | $60.30B | 52.9 | 59.8 | 2.0 | +4.2% |
| Ironwood Pharmaceuticals | $4.29 | −5.26% | $744.9M | 5.9 | 3.5 | 1.9 | +32.6% |
| Median | 29.4 | 31.6 | 2.0 | +18.4% |